Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
41556616 (PubMed )
Supplement: PRO-35-e70422-s002.xlsx › Table_S1
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Dubbury SJ et al.
Nature, 2018
Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre G et al.
Nature Genetics, 2018
30104763 (PubMed )
Supplement: NIHMS78219-supplement-3.xlsx › mutated_cases
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.
Riaz N et al.
Nature Communications, 2017
29021619 (PubMed )
Supplement: 41467_2017_921_MOESM5_ESM.xlsx › Sheet1
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Tien JF et al.
Nucleic Acids Research, 2017
28334900 (PubMed )
Supplement: gkx187_Supp.zip › nar-01703-a-2016-File011.pdf
Role and therapeutic potential of CDK12 in human cancers.
Chilà R et al.
Cancer Treatment Reviews, 2016
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T et al.
Cancer Research, 2016
26787835 (PubMed )
Supplement: 00085472can152128-sup-152923_2_supp_3283923_nztpsz.pdf
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM et al.
Nucleic Acids Research, 2015
Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM et al.
The Journal of Biological Chemistry, 2014
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I et al.
Cancer Research, 2014
Select a paper to view details